Merrimack Pharmaceuticals
MACK
$14.98
Share price
1.63%
Change (1 day)
18.98%
Change (1 year)
Categories
Operating Margin for Merrimack Pharmaceuticals (MACK)
Operating Margin as of May 2024 (TTM): -106.40%
According to Merrimack Pharmaceuticals's latest financial reports and stock price the company's current Operating Margin is -106.40%. At the end of 2016 the company had an Operating Margin of -106.41%.
Operating Margin history for Merrimack Pharmaceuticals from 2010 to 2016
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2016 | -106.41% | -35.73% |
| 2015 | -165.57% | 103.61% |
| 2014 | -81.32% | -70.27% |
| 2013 | -273.48% | 45.81% |
| 2012 | -187.56% | -19.46% |
| 2011 | -232.87% | -5.73% |
| 2010 | -247.03% | -89.89% |
| 2009 | -2,442.97% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 18.21% | -117.11% | 🇫🇷 France |
 Geron GERN | -23,808.90% | 22,276.79% | 🇺🇸 USA |
 Clovis Oncology CLVS | -163.43% | 53.60% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -30.78% | -71.07% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 0.00% | N/A | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.